Granulocyte colony stimulating factor - Xenetic Biosciences/SynBio

Drug Profile

Granulocyte colony stimulating factor - Xenetic Biosciences/SynBio

Alternative Names: Polysialic G-CSF - Xenetic Biosciences; StimuXen; SYN 20111504RU

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lipoxen Technologies; Serum Institute of India
  • Developer Serum Institute of India; SynBio; Xenetic Biosciences
  • Class Adjuvants; Glycoproteins; Granulocyte colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Neutropenia

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 16 Jun 2014 Granulocyte colony stimulating factor polysialic licensed to SynBio worldwide prior to April 2014
  • 15 Apr 2014 Preclinical trials in Neutropenia in Russia (Parenteral) prior to April 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top